Last reviewed · How we verify
Neostigmine + Glycopyrrolate
Neostigmine + Glycopyrrolate is a Acetylcholinesterase inhibitor with anticholinergic agent Small molecule drug developed by Merck Sharp & Dohme LLC. It is currently FDA-approved for Reversal of neuromuscular blockade induced by non-depolarizing neuromuscular blocking agents.
Neostigmine inhibits acetylcholinesterase to increase acetylcholine levels, while glycopyrrolate blocks muscarinic receptors to prevent cholinergic side effects.
Neostigmine inhibits acetylcholinesterase to increase acetylcholine levels, while glycopyrrolate blocks muscarinic receptors to prevent cholinergic side effects. Used for Reversal of neuromuscular blockade induced by non-depolarizing neuromuscular blocking agents during anesthesia, Myasthenia gravis.
At a glance
| Generic name | Neostigmine + Glycopyrrolate |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Acetylcholinesterase inhibitor with anticholinergic agent |
| Target | Acetylcholinesterase (neostigmine); Muscarinic acetylcholine receptors (glycopyrrolate) |
| Modality | Small molecule |
| Therapeutic area | Neuromuscular |
| Phase | FDA-approved |
Mechanism of action
Neostigmine is a reversible acetylcholinesterase inhibitor that increases acetylcholine concentration at the neuromuscular junction and in the central and peripheral nervous systems. Glycopyrrolate is an anticholinergic agent added to counteract the excessive muscarinic effects (salivation, bronchospasm, bradycardia) that would otherwise result from neostigmine alone. This combination is used to reverse neuromuscular blockade after anesthesia.
Approved indications
- Reversal of neuromuscular blockade induced by non-depolarizing neuromuscular blocking agents
Common side effects
- Bradycardia
- Hypotension
- Increased salivation
- Bronchospasm
- Muscle fasciculations
Key clinical trials
- Neostigmine and Glycopyrrolate for the Treatment of Headache After Dural Puncture (PHASE2)
- NMBA Reversal and Postoperative Urinary Retention
- Neuromuscular Blockade Comparison for GI-2 Recovery After Bowel Resection (PHASE4)
- The Impact of Sugammadex on Ileus After Abdominal Wall Reconstruction (PHASE4)
- Sugammadex vs Neostigmine Reversal in Pediatric Appendectomy (PHASE4)
- Pharmacokinetics of Neostigmine and Glycopyrrolate (EARLY_PHASE1)
- Transdermal Administration by a Novel Wireless Iontophoresis Device (EARLY_PHASE1)
- Sugammadex v.s. Neostigmine/Glycopyrrolate (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Neostigmine + Glycopyrrolate CI brief — competitive landscape report
- Neostigmine + Glycopyrrolate updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI
Frequently asked questions about Neostigmine + Glycopyrrolate
What is Neostigmine + Glycopyrrolate?
How does Neostigmine + Glycopyrrolate work?
What is Neostigmine + Glycopyrrolate used for?
Who makes Neostigmine + Glycopyrrolate?
What drug class is Neostigmine + Glycopyrrolate in?
What development phase is Neostigmine + Glycopyrrolate in?
What are the side effects of Neostigmine + Glycopyrrolate?
What does Neostigmine + Glycopyrrolate target?
Related
- Drug class: All Acetylcholinesterase inhibitor with anticholinergic agent drugs
- Target: All drugs targeting Acetylcholinesterase (neostigmine); Muscarinic acetylcholine receptors (glycopyrrolate)
- Manufacturer: Merck Sharp & Dohme LLC — full pipeline
- Therapeutic area: All drugs in Neuromuscular
- Indication: Drugs for Reversal of neuromuscular blockade induced by non-depolarizing neuromuscular blocking agents
- Compare: Neostigmine + Glycopyrrolate vs similar drugs
- Pricing: Neostigmine + Glycopyrrolate cost, discount & access